SUN PHARMACEUTICAL IND L
NSE₹1,869.60·SUNPHARMA·INE044A01036
Previous session · source 2026-09-19SnapshotPrice chart
fast lightweight viewSUNPHARMA 1M line chart. 14 bars, from 1,984.8 to 1,837.3, down 7.43 percent.
Market depth
live order book| Bid Price | Qty | Ask Price | Qty |
|---|---|---|---|
| 1,849.80BSE | 124 | 1,837.90NSE | 8 |
| 1,849.75BSE | 34 | 1,838.00NSE | 17 |
| 1,849.70BSE | 31 | 1,838.10NSE | 21 |
| 1,849.55BSE | 15 | 1,838.20NSE | 35 |
| 1,849.50BSE | 15 | 1,838.30NSE | 75 |
| 1,837.40NSE | 8 | 1,850.00BSE | 154 |
| 1,837.20NSE | 35 | 1,850.10BSE | 1 |
| 1,837.10NSE | 20 | 1,850.15BSE | 12 |
| 1,837.00NSE | 52 | 1,850.25BSE | 15 |
| 1,836.90NSE | 21 | 1,850.40BSE | 21 |
| Bid Total | 355 | Ask Total | 359 |
- 1,854.60
- Open
- 1,856.80
- High
- 1,834.60
- Low
- 1,869.60
- Close
Performance
Investor snapshot
fast read from available feedsUse this as a navigation aid. It summarizes feed observations, not a buy or sell view.
Financials
₹ croreRevenue and profit growth
latest Mar 2026Revenue growth
Net profit growth
Historical returns
computed from available OHLCCompany profile
Public company in Specialty Generics, part of the Pharmaceuticals sector.
Sun Pharmaceutical Industries Ltd., founded in 1983, is India's largest pharmaceutical company and the fourth largest specialty generic pharmaceutical firm globally. Headquartered in Mumbai, it manufactures branded generics, pure generics, specialty products, and APIs across 43 facilities worldwide. The company serves over 100 countries, with around 70% of revenue from international markets, primarily the US and India. Key therapeutic areas include neuropsychiatry, cardiology, oncology, dermatology, and anti-infectives. Major acquisitions like Ranbaxy Laboratories in 2014 and Taro Pharmaceuticals have bolstered its position. It employs over 43,000 people and reported $6.3 billion in revenue for FY2024.
- India's No.1 pharma company by market cap
- 4th largest global specialty generics player
- 43 global manufacturing sites
- 70% revenue from exports